AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11521914
Drug: Expedient and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expedient and appropriate early treatment of fractures
Trial: 2465076
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) with low-dose leucovorin (20 mg/m2) intravenously for 5 days
Trial: 2465076
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) with high-dose leucovorin (200 mg/m2) intravenously for 5 days
Trial: 2465076
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) alone (500 mg/m2 for 5 days)
Trial: 2465076
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) with leucovorin (both doses)
Trial: 9954
Drug: Methyldopa (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (250 mg and 500 mg)
Trial: 30387193
Drug: 12-hour overnight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-hour overnight abstinence from snus (1 g of snus, 8 mg/g of nicotine administered 25 minutes before exercise)
Trial: 30387193
Drug: Satiety condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Satiety condition (1 g of snus, 8 mg/g of nicotine administered 25 minutes before exercise)
Trial: 28590567
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D insufficiency (<50 nmol/L) in late pregnancy
Trial: 16861094
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg PO QD
Trial: 16861094
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg PO QD
Trial: 9156268
Drug: Donor lymphocyte
RxNorm normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donor lymphocyte infusions (DLI) with a large dose of donor lymphocytes (≥ 1 x 10(8)/kg) in group A (n = 8)
Trial: 9156268
Drug: Donor lymphocyte
RxNorm normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donor lymphocyte infusions (DLI) with escalating doses of cells (2 x 10(5) up to 2 x 10(8)/kg) in group B (n = 10)
Trial: 9156268
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (DLI with escalating doses)
Trial: 31736428
Drug: Active supplement
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active supplement containing Bacopa monniera, Panax quinquefolius ginseng, and whole coffee fruit extract
Trial: 30241504
Drug: Sodium nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium nitrite (NaNO2) infusion at 240 μg/kg/hour for 2 hours
Trial: 30241504
Drug: Allopurinol 150
RxNorm normalized name: allopurinol 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 150 mg twice daily (TD)
Trial: 30241504
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg TD
Trial: 30241504
Drug: Acetazolamide 250
RxNorm normalized name: acetazolamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250 mg TD
Trial: 17640489
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg domperidone as free base with 20 mg omeprazole twice daily
Trial: 17640489
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg domperidone as maleate salt with 20 mg omeprazole twice daily
Trial: 17640489
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg domperidone as free base alone
Trial: 17640489
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg domperidone as maleate salt alone
Trial: 17640489
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg domperidone as free base with omeprazole
Trial: 15915352
Drug: Probenecid (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probenecid (500 mg, twice daily for 10 days)
Trial: 11914204
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg dose of levofloxacin by mouth preoperatively
Trial: 2816479
Drug: Estrogen monotherapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen monotherapy (n = 20)
Trial: 2816479
Drug: Continuously combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuously combined estrogen/progestogen therapy (n = 20)
Trial: 2816479
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for estrogen monotherapy (n = 25)
Trial: 2816479
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for continuously combined estrogen/progestogen therapy (n = 23)
Trial: 2816479
Drug: Post-treatment (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-treatment (3 months after hormone withdrawal)
Trial: 26591395
Drug: Switch therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch therapy (SWT) - switching from IV to oral antibiotics within 24 hours after clinical improvement
Trial: 26591395
Drug: Switch therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch therapy (SWT)
Trial: 24219860
Drug: Rituximab (anti-CD20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (anti-CD20 molecule)
Trial: 22808810
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg daily for 3 days
Trial: 22808810
Drug: Cut-off value
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cut-off value of 800 ml for RU
Trial: 16786236
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin therapy (atorvastatin 80 mg/day)
Trial: 16786236
Drug: Moderate statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate statin therapy (pravastatin 40 mg/day)
Trial: 16786236
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with LDL < 70 mg/dL
Trial: 16786236
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with CRP < 2 mg/L
Trial: 16786236
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with LDL < 70 mg/dL and CRP < 2 mg/L
Trial: 15383180
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of travoprost 0.004% once daily and brinzolamide 0.1% twice daily (TB group: 22 patients)
Trial: 15383180
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of latanoprost 0.005%/timolol 0.5% once daily (LT group: 22 patients)
Trial: 12539556
Drug: Xiaokuiling prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaokuiling prescription (XKL)
Trial: 9397242
Drug: OPC‐21268 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC‐21268 (100 mg)
Trial: 2822298
Drug: Methoxamine (alpha‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methoxamine (alpha‐1 adrenoceptor agonist)
Trial: 2822298
Drug: Thymoxamine (alpha‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoxamine (alpha‐1 adrenoceptor antagonist)
Trial: 22395731
Drug: Dopamine agonist
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonist (levodopa)
Trial: 19732095
Drug: Placebo (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (300 mg)
Trial: 7839475
Drug: Inhaled racemic
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled racemic epinephrine
Trial: 12499338
Drug: Basic meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic meal with 50 g pork
Trial: 12499338
Drug: Basic meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic meal with 75 g pork
Trial: 12499338
Drug: Basic meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic meal with 25 g pork
Trial: 11096386
Drug: Epidermal cooling
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidermal cooling with IPL treatment
Trial: 11096386
Drug: Non-cooled IPL
RxNorm normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-cooled IPL treatment
Trial: 11096386
Drug: Crossover treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover treatment with cooling
Trial: 8558209
Drug: G‐CSF 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF 5 micrograms/kg on days 1 to 12 and GM‐CSF at 0.5, 1, or 5 micrograms/kg on days 7 to 12
Trial: 8558209
Drug: GM‐CSF 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF 5 micrograms/kg on days 1 to 12 and G‐CSF 5 micrograms/kg on days 7 to 12
Trial: 8558209
Drug: G‐CSF added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF added to patients already receiving GM‐CSF (cohort 4)
Trial: 8558209
Drug: GM‐CSF added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF added to patients already receiving G‐CSF
Trial: 31030870
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (neutral WSAP task or treatment as usual)
Trial: 22866291
Drug: 5 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 × 5 mm dental implants with a novel nanostructured calcium‐incorporated titanium surface
Trial: 22866291
Drug: at least
RxNorm normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: at least 5 × 10 mm‐long implants in augmented bone
Trial: 19682360
Drug: Oral methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methadone (MMT)
Trial: 30951166
Drug: PrabotulinumtoxinA (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrabotulinumtoxinA (20 U, 0.1 mL injected into each of 5 glabellar sites)
Trial: 30951166
Drug: OnabotulinumtoxinA (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnabotulinumtoxinA (20 U, 0.1 mL injected into each of 5 glabellar sites)
Trial: 27244762
Drug: GnRH‐a (Triptorelin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH‐a (Triptorelin) subcutaneous daily injections starting on day 1-2 of the cycle (Group A)
Trial: 27244762
Drug: GnRH‐a (Triptorelin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH‐a (Triptorelin) subcutaneous daily injections starting on day 20-22 of the previous cycle (Group B)
Trial: 27244762
Drug: GnRH‐a (Triptorelin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH‐a (Triptorelin) subcutaneous daily injections (both groups)
Trial: 17610534
Drug: Atomoxetine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (40 mg qd for 3 days, then 80 mg qd for 7 days)
Trial: 10448545
Drug: Lysine acetylsalicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine acetylsalicylic acid (L-ASA) 1.8 g i.v. (1 g acetylsalicylic acid)
Trial: 30632837
Drug: Obinutuzumab plus
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab plus chemotherapy (G + chemo)
Trial: 30632837
Drug: Rituximab plus
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab plus chemotherapy (R + chemo)
Trial: 22707132
Drug: Levofloxacin (LVFX)
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin (LVFX) 250 mg orally
Trial: 19166694
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (1,500 mg/day) plus placebo
Trial: 19166694
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (1,500 mg/day) plus gemfibrozil (1,200 mg/day)
Trial: 17151802
Drug: Omeprazole (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (high-dose intravenous proton pump inhibitor)
Trial: 17151802
Drug: Omeprazole (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (high-dose intravenous proton pump inhibitor) + Misoprostol (600 microg/day)
Trial: 15057738
Drug: MRA (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRA (8 mg/kg biweekly)
Trial: 11442185
Drug: Topical verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical verapamil (0.25%)
Trial: 9758438
Drug: Iodine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine (0.5 mg/day)
Trial: 9758438
Drug: Levo-thyroxine (T4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levo-thyroxine (T4) (0.125 mg/day)
Trial: 3044833
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus Poly(A).Poly(U)
Trial: 27878630
Drug: cMyBP‐C plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cMyBP‐C plasma levels measured at admission (122.44 ± 41.01 ng/ml)
Trial: 27878630
Drug: cMyBP‐C plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cMyBP‐C plasma levels measured after treatment (71.38 ± 49.68 ng/ml)
Trial: 27878630
Drug: cMyBP‐C plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cMyBP‐C plasma levels at admission (cutoff point of 45 ng/ml)
Trial: 27878630
Drug: cMyBP‐C plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cMyBP‐C plasma levels at admission (cutoff point of 152 ng/ml)
Trial: 26142168
Drug: Combined physical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined physical and occupational therapy (Group B, n=30)
Trial: 26142168
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy only (Group A, n=31)
Trial: 11015511
Drug: Early enteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early enteral iron supplementation (EI) of 2 to 6 mg/kg/day
Trial: 6354151
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) high‐dosage cyclophosphamide
Trial: 26932324
Drug: Cessation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation treatment
Trial: 15461066
Drug: Stage IIa
RxNorm normalized name: autoprothrombin IIA
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage IIa PAD treatment
Trial: 15461066
Drug: Stage IIb
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage IIb PAD treatment
Trial: 15461066
Drug: Stage III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage III PAD treatment
Trial: 15461066
Drug: Stage IV
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage IV PAD treatment
Trial: 27740724
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment costs
Trial: 2606594
Drug: MaxEPA fish
RxNorm normalized name: MAXEPA FISH OIL CONCENTRATE CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MaxEPA fish oil diet (6 g daily for 6 weeks)
Trial: 27176943
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity on Prescription (PaP) with conventional treatment
Trial: 20644583
Drug: Continuous renal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous renal replacement therapy (CRRT) with effluent flow rates >25 ml/kg per hour
Trial: 18540016
Drug: Micro-implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-implants
Trial: 16411387
Drug: Otamixaban (escalating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otamixaban (escalating intravenous doses, 6-hour infusions: 1.7 to 183 microg/kg/h)
Trial: 16411387
Drug: Otamixaban (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otamixaban (bolus dose: 30 or 120 microg/kg with 6-hour infusion: 60 or 140 microg/kg/h)
Trial: 8839525
Drug: Inhaled beta-agonists
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beta-agonists
Trial: 6432291
Drug: Prednisone plus
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone plus triple treatment (sodium fluoride, calcium, and vitamin D)
Trial: 6432291
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Prednisone plus triple treatment and Only prednisone)
Trial: 22369557
Drug: Long-term low
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term low dose aspirin therapy (75 mg and 150 mg)
Trial: 22369557
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not taking aspirin)
Trial: 11966498
Drug: Ranitidine, 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 75 mg
Trial: 7789484
Drug: Azithromycin, 500
RxNorm normalized name: Azithromycin, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, 500 mg q.d. oral therapy for 3 days
Trial: 7789484
Drug: Clarithromycin, 250
RxNorm normalized name: Clarithromycin, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin, 250 mg b.i.d. oral therapy for 10 +/- 2 days
Trial: 2887328
Drug: Cetirizine, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine, 20 mg
Trial: 29877199
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF)-mobilized PBMNC transplantation combined with standard of care (SOC)
Trial: 26477842
Drug: Bevacizumab (Avastin)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (Avastin) 1.25 mg
Trial: 26477842
Drug: Ranibizumab (Lucentis)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab (Lucentis) 0.5 mg
Trial: 20224475
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (0.625 mg)
Trial: 18160813
Drug: Mouthrinse with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthrinse with 0.2% NaF solution
Trial: 18160813
Drug: Gels (0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gels (0.2% or 0.32%) alone and in combination with brushing
Trial: 18160813
Drug: Interdental brush
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interdental brush with fluoride gel after toothbrushing
Trial: 15786539
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with rabeprazole (10 mg twice daily), clarithromycin (200 mg twice daily) and amoxicillin (750 mg twice daily)
Trial: 15786539
Drug: Sofalcone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofalcone (100 mg thrice daily) plus the triple therapy
Trial: 15786539
Drug: Polaprezinc (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polaprezinc (150 mg twice daily) plus the triple therapy
Trial: 11389501
Drug: New antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antifungal agents (specific agents not mentioned)
Trial: 9159561
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg rifampicin once daily for 5 days
Trial: 3655310
Drug: 12-week intramuscular
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week intramuscular lymphoblastoid interferon treatment
Trial: 3655310
Drug: 24-week intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-week intramuscular lymphoblastoid interferon treatment
Trial: 31304593
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg rectal misoprostol at urinary catheter insertion plus 400 μg rectally after abdominal closure (preoperative group, n=100)